Everolimus for the treatment of advanced renal cell carcinoma

被引：19

作者：

Amato, Robert ^{[1
]}

机构：

[1] UT Med Sch Houston Internal Med, Div Oncol, Houston, TX 77030 USA

来源：

EXPERT OPINION ON PHARMACOTHERAPY | 2011年 / 12卷 / 07期

关键词：

ENDOTHELIAL GROWTH-FACTOR; PROGNOSTIC-FACTORS; MAMMALIAN TARGET; BREAST-CANCER; MTOR; INHIBITOR; PATHWAY; SURVIVAL; RELEVANCE; EFFICACY;

D O I：

10.1517/14656566.2011.571382

中图分类号：

R9 [药学];

学科分类号：

100702 [药剂学];

摘要：

Areas covered: The function of mTOR and its inhibition, the early development trials of everolimus, the Phase II trial that lead to the Phase III study and ultimately to FDA approval are all discussed in this review. Literature utilized for this review consists of PUBMED for both description of the mTOR pathway and its role, in addition to publications using everolimus in RCC. Expert opinion: Everolimus is currently the only agent with a proven progression-free survival improvement for patients who progressed on a vascular endothelial growth factor receptor--tyrosine kinase inhibitor. Future studies may further shed light on the most optimal use of everolimus.

引用

页码：1143 / 1155

页数：13

共 40 条

[1]

A Phase 2 Study With a Daily Regimen of the Oral mTOR Inhibitor RAD001 (Everolimus) in Patients With Metastatic Clear Cell Renal Cell Cancer [J].

Amato, Robert J. ;

Jac, Jaroslaw ;

Giessinger, Sarah ;

Saxena, Somyata ;

Willis, James P. .

CANCER, 2009, 115 (11) :2438-2446

[2]

[Anonymous], J CLIN ONCOL S

[3]

[Anonymous], J CLIN ONCOL S

[4]

Effect of papillary and chromophobe cell type on disease-free survival after nephrectomy for renal cell carcinoma [J].

Beck, SDW ;

Patel, MI ;

Snyder, ME ;

Kattan, MW ;

Motzer, RJ ;

Reuter, VE ;

Russo, P .

ANNALS OF SURGICAL ONCOLOGY, 2004, 11 (01) :71-77

[5]

The mTOR inhibitor RAD001 sensitizes tumor cells to DNA-damaged induced apoptosis through inhibition of p21 translation [J].

Beuvink, I ;

Boulay, A ;

Fumagalli, S ;

Zilbermann, F ;

Ruetz, S ;

O'Reilly, T ;

Natt, F ;

Hall, J ;

Lane, HA ;

Thomas, G .

CELL, 2005, 120 (06) :747-759

[6]

The TOR pathway: A target for cancer therapy [J].

Bjornsti, MA ;

Houghton, PJ .

NATURE REVIEWS CANCER, 2004, 4 (05) :335-348

[7]

BOS JL, 1989, CANCER RES, V49, P4682

[8]

Renal-cell carcinoma - Molecular pathways and therapies [J].

Brugarolas, James .

NEW ENGLAND JOURNAL OF MEDICINE, 2007, 356 (02) :185-187

[9]

Elucidating TOR signaling and rapamycin action:: lessons from Saccharomyces cerevisiae [J].

Crespo, JL ;

Hall, MN .

MICROBIOLOGY AND MOLECULAR BIOLOGY REVIEWS, 2002, 66 (04) :579-+

[10]

Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer [J].

Cunningham, D ;

Humblet, Y ;

Siena, S ;

Khayat, D ;

Bleiberg, H ;

Santoro, A ;

Bets, D ;

Mueser, M ;

Harstrick, A ;

Verslype, C ;

Chau, I ;

Van Cutsem, E .

NEW ENGLAND JOURNAL OF MEDICINE, 2004, 351 (04) :337-345

← 1 2 3 4 →